(S)-四氢-alpha-(1-甲基乙基)-2-氧代- | 192800-77-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-四氢-alpha-(1-甲基乙基)-2-氧代-
• 英文名称: 2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl chloride
• 英文别名: 2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl chloride；2S-(1-Tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl Chloride；(2S)-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanoyl chloride
• CAS: 192800-77-4
• 化学式: C₉H₁₅ClN₂O₂
• 分子量: 218.683
• InChiKey: CVUOJBKULXTCRU-ZETCQYMHSA-N

物化性质

• 溶解度：
  可溶于丙酮、氯仿

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-四氢-alpha-(1-甲基乙基)-2-氧代- 在 咪唑 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 洛匹那韦
  参考文献：
  名称：

  WO2006/90264

  摘要：

  公开号：
• 作为产物：
  描述：

  (2S)-(1-四氢嘧啶-2-酮)-3-甲基丁酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.25h， 生成 (S)-四氢-alpha-(1-甲基乙基)-2-氧代-
  参考文献：
  名称：

  NOVEL POLYMORPHS OF LOPINAVIR

  摘要：

  本发明提供了一种洛匹那韦的新型环己烷溶剂结晶形式及其制备方法。本发明还提供了一种新型的去溶剂晶体形式的洛匹那韦，其制备方法以及含有它的制药组合物。例如，将洛匹那韦环己烷溶剂结晶体在100℃下加热10小时，得到洛匹那韦去溶剂晶体形式H1。

  公开号：

  US20110294839A1

文献信息

• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：EP1170289A2

  公开（公告）日：2002-01-09

  A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

  披露了一种包含公式（II）取代基的化合物，作为一种HIV蛋白酶抑制剂。还披露了用于制造此类化合物的中间体以及制造此类中间体的过程。
• Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2‘ Ligands in Pseudosymmetric Dipeptide Isosteres
  作者：G. S. Kiran Kumar Reddy、Akbar Ali、Madhavi N. L. Nalam、Saima Ghafoor Anjum、Hong Cao、Robin S. Nathans、Celia A. Schiffer、Tariq M. Rana

  DOI：10.1021/jm070284z

  日期：2007.9.1

  A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have been synthesized and evaluated. The inhibitors were designed by incorporating N-phenyloxazolidinone-5-carboxamides into the hydroxyethylene and (hydroxyethyl)hydrazine dipeptide isosteres as P2 and P2' ligands. Compounds with (S)-phenyloxazolidinones attached at a position proximal to the central hydroxyl group showed low nM inhibitory activities against wild-type HIV-1 protease. Selected compounds were further evaluated for their inhibitory activities against a panel of multidrug-resistant protease variants and for their antiviral potencies in MT-4 cells. The crystal structures of lopinavir (LPV) and two new inhibitors containing phenyloxazolidinone-based ligands in complex with wild-type HIV-1 protease have been determined. A comparison of the inhibitor-protease structures with the LPV-protease structure provides valuable insight into the binding mode of the new inhibitors to the protease enzyme. Based on the crystal structures and knowledge of structure -activity relationships, new inhibitors can be designed with enhanced enzyme inhibitory and antiviral potencies.
• Synthesis of HIV Protease Inhibitor ABT-378 (Lopinavir)
  作者：Eric J. Stoner、Arthur J. Cooper、Daniel A. Dickman、Lawrence Kolaczkowski、John E. Lallaman、Jih-Hua Liu、Patricia A. Oliver-Shaffer、Ketan M. Patel、Joseph B. Paterson、Daniel J. Plata、David A. Riley、Hing. L. Sham、Peter J. Stengel、Jien-Heh J. Tien

  DOI：10.1021/op990202j

  日期：2000.7.1

  A large scale process for the synthesis of HIV protease inhibitor candidate ABT-378 has been developed which utilizes an intermediate common to the synthesis of ritonavir, Abbott's first generation compound, The synthesis relies on the sequential acylation of this intermediate which is carried through as a mixture of diastereomers until the penultimate step. A synthesis of acid 5, derived from L-valine, is also reported.
• WO2006/100552
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of ABT-378, an HIV Protease Inhibitor Candidate:  Avoiding the Use of Carbodiimides in a Difficult Peptide Coupling
  作者：Eric J. Stoner、Peter J. Stengel、Arthur J. Cooper

  DOI：10.1021/op980214p

  日期：1999.3.1

  An alternative to carbodiimide-mediated peptide coupling protocols has been developed for a carboxylic acid prone to decomposition by polymerization. This method, involving the in situ generation of an acyl, imidazolide, has been applied to the preparation of a lead clinical HIV protease inhibitor candidate, ABT-378. The nature of the polymerization and optimization of the new reaction conditions are presented.